Trial reportAddiction (Abingdon, England)2012
Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.
Trial report in Addiction (Abingdon, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Maintenance agonist treatments for opiate-dependent pregnant women.The Cochrane database of systematic reviews · 2020Pooled it
- Guideline
- Antenatal Exposure to Medication for Opioid Use Disorder and Infant Outcomes in the Eat, Sleep, Console for Neonatal Opioid Withdrawal Randomized Controlled Trial.The Journal of pediatrics · 2026Trial
- Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention.Drug and alcohol dependence · 2013Trial
- Prenatal Opioid Exposure and Neonatal Opioid Withdrawal Syndrome.Advances in experimental medicine and biology · 2026Review
- From morphine to buprenorphine - Modeling opioid use disorder and its treatment during pregnancy: Effects on maternal care and offspring neurodevelopment in a translational rodent model.Pharmacology, biochemistry, and behavior · 2025Article
- Systemic barriers and stigma: Healthcare provider perspectives on perinatal and neonatal care in the fentanyl crisis.Journal of substance use and addiction treatment · 2025Article
- The effects of buprenorphine and morphine during pregnancy: Impact of exposure length on maternal brain, behavior, and offspring neurodevelopment.Neuropharmacology · 2024Article
- Neonatal Abstinence Signs during Treatment: Trajectory, Resurgence and Heterogeneity.Children (Basel, Switzerland) · 2024Article
- The cell-permeant antioxidant D-thiol ester D-cysteine ethyl ester overcomes physical dependence to morphine in male Sprague Dawley rats.Frontiers in pharmacology · 2024Article
- The epigenetic signatures of opioid addiction and physical dependence are prevented by D-cysteine ethyl ester and betaine.Frontiers in pharmacology · 2024Article
- Investigating the neurobiology of maternal opioid use disorder and prenatal opioid exposure using brain organoid technology.Frontiers in cellular neuroscience · 2024Review
- Neonatal Abstinence Syndrome in Infants with Prenatal Exposure to Methadone versus Buprenorphine.Children (Basel, Switzerland) · 2023Article
- Methadone alters transcriptional programs associated with synapse formation in human cortical organoids.Translational psychiatry · 2023Article
- Opioid, methamphetamine, and polysubstance use: perinatal outcomes for the mother and infant.Frontiers in pediatrics · 2023Review
- L-cysteine ethyl ester prevents and reverses acquired physical dependence on morphine in male Sprague Dawley rats.Frontiers in pharmacology · 2023Article
- Lipophilic analogues of D-cysteine prevent and reverse physical dependence to fentanyl in male rats.Frontiers in pharmacology · 2023Article
- Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy.The New England journal of medicine · 2022Article
- Article
- Study design and rationale for a randomized controlled trial to assess effectiveness of stochastic vibrotactile mattress stimulation versus standard non-oscillating crib mattress for treating hospitalized opioid-exposed newborns.Contemporary clinical trials communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 1 country.
Funding
Abstract
aimsTo compare the profile of signs of neonatal abstinence syndrome (NAS) in methadone- versus buprenorphine-exposed infants. DESIGN, SETTING AND
participantsSecondary analysis of NAS data from a multi-site, double-blind, double-dummy, flexible-dosing, randomized clinical trial. Data from a total of 129 neonates born to opioid-dependent women who had been assigned to receive methadone or buprenorphine treatment during pregnancy were examined. MEASUREMENTS: For 10 days after delivery, neonates (methadone = 72, buprenorphine = 57) were assessed regularly using a 19-item modified Finnegan scale. Data from neonates who required pharmacological treatment (methadone = 41, buprenorphine = 27) were included up to the time treatment was initiated. The incidence and mean severity of the total NAS score and each individual sign of NAS were calculated and compared between medication conditions, as was the median time until morphine treatment initiation among treated infants in each condition.
findingsTwo NAS signs (undisturbed tremors and hyperactive Moro reflex) were observed significantly more frequently in methadone-exposed neonates and three (nasal stuffiness, sneezing, loose stools) were observed more frequently in buprenorphine-exposed neonates. Mean severity scores on the total NAS score and five individual signs (disturbed and undisturbed tremors, hyperactive Moro reflex, excessive irritability, failure to thrive) were significantly higher among methadone-exposed neonates, while sneezing was higher among buprenorphine-exposed neonates. Among treated neonates, methadone-exposed infants required treatment significantly earlier than buprenorphine-exposed infants (36 versus 59 hours postnatal, respectively).
conclusionsThe profile of neonatal abstinence syndrome differs in methadone- versus buprenorphine-exposed neonates, with significant differences in incidence, severity and treatment initiation time. Overall, methadone-exposed neonates have a more severe neonatal abstinence syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.